Day: September 28, 2021

Partnership to focus on empowering women to take ownership of their health and healthcare options PRINCETON, N.J., Sept. 28, 2021 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced today a partnership with U.S. Women’s Soccer legend, Carli Lloyd. The partnership with Agile will focus on bringing awareness to women’s health topics, and Agile’s commitment to elevating women’s healthcare. Lloyd, who will play her final game for the U.S. Women’s National Team on October 26th against South Korea, was attracted to the company’s mission of addressing the healthcare needs of today’s women. “I’m excited to be partnering with a company solely dedicated to women’s health,” said Lloyd. “I aim to work with organizations that focus on things I care about, and staying healthy has been a priority...

Also Receives Amended Drilling Permit for Follow-Up Drilling at Recent High-Grade Discovery at Eastside RENO, Nevada, Sept. 28, 2021 (GLOBE NEWSWIRE) — Allegiant Gold Ltd. (“Allegiant” or the “Company”) (AUAU: TSX-V) (AUXXF: OTCQX) is very pleased to announce the receipt of two permits allowing for a significant expansion of drilling and operations at its Flagship Eastside Project (Inferred ounces of 1.4M Au and 8.7M Ag*) near the town of Tonopah, Nevada. The first permit expands the Plan-of-Operations (“PoO”) from the previous 600 acres to over 3,676 acres around the Original Pit Zone. The second permit received amends the existing drill target plan within the Original Pit Zone and will allow Allegiant to drill up to 14 new diamond core holes to test the recently discovered high-grade zone announced on May 26, 2021. Highlights...

RICHLAND, Wash., Sept. 28, 2021 (GLOBE NEWSWIRE) — The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131 has been included in ABS’s highly respected consensus guidelines. Because Cesium-131 seeds were not available as a treatment until 2004, long-term outcomes following Cesium-131 prostate brachytherapy seeds have only recently been available. ABS does not rank or endorse any specific treatment option, but rather is focused on evaluating evidence and providing insight into research surrounding the use of brachytherapy in addressing malignant and benign conditions. Reacting to the newly published, evidence-based consensus statement, Isoray CEO Lori Woods noted the...

DRAPER, Utah, Sept. 28, 2021 (GLOBE NEWSWIRE) — HealthEquity (NASDAQ: HQY), the nation’s largest health savings account (HSA) non-bank custodian, today announced that it has commenced, subject to market and other conditions, an offering of $500 million aggregate principal amount of its senior notes due 2029. It is expected that the senior notes will be guaranteed by certain of HealthEquity’s subsidiaries on a senior unsecured basis. HealthEquity intends to use the net proceeds from the offering, together with cash on hand and borrowings under new credit facilities, to refinance outstanding amounts under its existing term loan and/or for general corporate purposes. The senior notes and related guarantees are being offered only to investors who are reasonably believed to be “qualified institutional buyers” in reliance on the exemption...

Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab Full data to be presented at American Academy of Ophthalmology’s Retina Subspecialty Meeting, RET13 – Section X: Late Breaking Developments, Part II on November 13th at 9:17 AM ETISELIN, N.J., Sept. 28, 2021 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced new 12-month safety data from the pivotal Phase 3 NORSE TWO trial that further confirm the strong safety profile in this study of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for treatment of neovascular age-related macular degeneration (wet AMD). In...

JACKSONVILLE, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) — Regency Centers Corporation (The “Company”) (NASDAQ: REG) will announce its Third Quarter 2021 earnings results on Thursday, November 4, 2021, after the market closes. The Company’s earnings release and supplemental information package will be posted on the Investor Relations section of the Company’s website – investors.regencycenters.com. The Company will host an earnings conference call on Friday, November 5, 2021, at 11:00 a.m. ET.Third Quarter 2021 Earnings Conference CallDate:   Friday, November 5, 2021Time:   11:00 a.m. ETDial#:   877-407-0789 or 201-689-8562Webcast:   investors.regencycenters.com     Replay Webcast Archive: Investor Relations page under Webcasts & Presentations About Regency Centers Corporation (NASDAQ: REG) Regency Centers is...

Study to focus on women of African American descent for expanded polygenic risk test MELBOURNE, Australia, Sept. 28, 2021 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business today announced that they have entered into a strategic collaboration with the Institute of Public Health in St Louis USA for the purpose of expanding the predictive capabilities of the GeneType for Breast Cancer product to include women of African descent. Highlights:GENE self-funding collaborative study to enable expanded risk testing for populations of African descent as part of our commitment to ethnic diversity Addressing underlying and underserved need to include diverse population studies within risk testing protocols and applications Designed...

28 September 2021Announcement no. 326 Capital increase in Rovsing A/S The board of directors of Rovsing A/S has according to clause 5.1(b) in the company’s articles of association decided to increase the company’s share capital with nominally DKK 94,600, divided into 1,892 shares of nominally DKK 50.00 each. The capital increase will be subscribed by Dyregårdsvej 2 ApS, CVR no. 21 05 85 99, and paid by way of converting DKK 199,908.72 in debt. The debt originates from a settlement agreement of 1 September 2021 between Rovsing A/S and Dyregårdsvej 2 ApS regarding the company’s payment of re-establishment costs related to the terminated lease located at Dyregårdsvej 2, 2740 Skovlunde. According to the settlement agreement, Rovsing A/S is obliged to pay DKK 270,000 to Dyregårdsvej 2 ApS of which DKK 199,908.72 has now been converted into...

Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models Initiation of a Phase 1 therapeutic clinical trial planned for 1H2022 INDIANAPOLIS, Sept. 28, 2021 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today released additional preclinical data from its fibroblast activation protein-alpha (FAP-alpha) inhibitor program called PNT2004. The new data demonstrates best-in-class characteristics including rapid and persistent tumor targeting with very low retention in normal tissues. Over the duration of the preclinical study, complete tumor regression and prolonged survival were observed. Based on this exciting preclinical...